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The synthesis of the subunits of the C1 complex (C1q, C1s, C1r), and its regulator C1
inhibitor (C1-Inh) by human monocytes has been previously established. However, surface
expression of these molecules by monocytes has not been shown. Using ﬂow cytome-
try and antigen-capture enzyme-linked immunosorbent assay, we show here for the ﬁrst
time that, in addition to C1q, peripheral blood monocytes, and the monocyte-derived U937
cells express C1s and C1r, as well as Factor B and C1-Inh on their surface. C1s and C1r
immunoprecipitated with C1q, suggesting that at least some of the C1q on these cells
is part of the C1 complex. Furthermore, the C1 complex on U937 cells was able to trig-
ger complement activation via the classical pathway. The presence of C1-Inh may ensure
that an unwarranted autoactivation of the C1 complex does not take place. Since C1-Inh
closely monitors the activation of the C1 complex in a sterile or infectious inﬂammatory
environment, further elucidation of the role of C1 complex is crucial to dissect its function
in monocyte, dendritic cell, and T cell activities, and its implications in host defense and
tolerance.
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INTRODUCTION
C1q (460 kDa) is a collagen-like, hexameric glycoprotein and con-
sists of similar, but distinct polypeptide chains 6A, 6B, and 6C that
form 6ABC triple helices (Brodsky-Doyle et al., 1976; Reid, 1989).
C1q contains immunoglobulin (Ig)G/IgM binding sequences in
its globular head region, which enable it to bind to immune com-
plexes and engage in complement-mediated microbial killing and
phagocytosis (Leist-Welsh and Bjornson, 1982; Bobak et al., 1987).
As a result, C1q deﬁciency is associated with increased susceptibil-
ity to infections includingotitismedia,meningitis, andpneumonia
(Kuis et al., 1988; Prellner et al., 1989;Vassallo et al., 2007; Pickering
et al., 2008).
C1q circulates in plasma at a concentration of 70–160μg/ml
(Hughes-Jones, 1977; Schuller and Helary, 1983; Dillon et al.,
2009), but like other components of innate immunity, it is pro-
duced in higher concentrations at inﬂammatory sites, predomi-
nantly bymacrophages and dendritic cells (DCs; Bensa et al., 1983;
Schwaeble et al., 1995; Kaul and Loos, 2001; Vegh et al., 2003;
Castellano et al., 2004). Approximately 80% of C1q contained
in the plasma is associated with the Ca2+-dependent C1r2–C1s2
tetramer (360 kDa) to form the multimeric C1 complex, the ﬁrst
Abbreviations: cC1qR/CR, receptor for the collagen tail of C1q (calreticulin);
gC1q, globular heads of C1q; gC1qR, receptor for the globular heads of C1q; pAb,
polyclonal antibody.
component of the classical complement system (Muller-Eberhard
andKunkel, 1961; Lepowet al., 1963;Calcott andMuller-Eberhard,
1972; Reid and Porter, 1976; Reid et al., 1982; Sjoholm et al.,
1985; Weiss et al., 1986). However, while C1q is traditionally
known as the recognition unit of the classical complement path-
way, it also plays a role in the antibody-dependent adaptive and
antibody-independent innate arm of immunity.
Deﬁciencies of any of the components of the C1 complex (C1q,
C1s, or C1r) are considered to be strong susceptibility factors for
systemic lupus erythematosus (SLE; Lee et al., 1978; Steinsson
et al., 1983; Fremeaux-Bacchi et al., 1996; Walport et al., 1998;
Cortes-Hernandez et al., 2004; Ghebrehiwet and Peerschke, 2004;
Amano et al., 2008). In addition, a large portion of SLE patients
have high afﬁnity autoantibodies to C1 complex components (He
and Lin, 1998; Walport et al., 1998; Walport, 2002). Although
most studies suggest that it is the failure to properly clear apop-
totic cells in the absence of C1q that results in autoimmunity
(Hurst et al., 1984;Walport et al., 1998), recent observations chal-
lenge this idea. For example, disruption of other apoptotic uptake
processes, such as those mediated by CD14 (Devitt et al., 2004),
β3 or β5 integrin (Lucas et al., 2006), and mannose-binding lectin
(Stuart et al., 2005), all result in accumulation of apoptotic bod-
ies without triggering autoimmunity. Therefore, in addition to
recognition and clearance of apoptotic bodies, C1q and the C1
complex play an as yet unidentiﬁed role in regulating the acquired
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immune response and thus maintaining tolerance. Since imma-
ture DCs (iDCs) and macrophages are the most abundant sources
of C1q, we hypothesize that local production of C1q by these cells
serves as an autocrine signaling mechanism, which induces cel-
lular responses by iDCs, macrophages, and their precursors (i.e.,
monocytes) through interactions with surface receptors (Hosszu
et al., 2010).
Biosynthesis of the multimolecular C1 complex and its reg-
ulator, C1 inhibitor, by human monocytes has been previously
shown (Bensa et al., 1983;Randazzo et al., 1985;Tenner andVolkin,
1986; Drouet and Reboul, 1989; Gulati et al., 1993; Lu et al., 1996;
Moosig et al., 2006). Recently, we have found that monocytes
freshly isolated from peripheral blood (PB) carry C1q on their
surface (Hosszu et al., 2010). Since monocytes serve a critical role
in adaptive and innate immunity not only by serving as precur-
sors of macrophages and myeloid DCs, but also by their function
in phagocytosis, antigen processing, and presentation, as well as
secretion of cytokines, we sought to further explore the functional
signiﬁcance of such extracellular C1q on these cells. The data pre-
sented here show that not only C1q, but the entire multimolecular
C1 complex is present on the surface of monocytes and suggest a
novel role for C1q within this complex as a molecular sensor of
“danger” signals. The fact that surface expressed C1 complex on
U937 cells was able to activate the classical complement cascade
suggests that surface-associated C1 complex initiates complement
ﬁxation in the presence of an extracellular Ag and thus sup-
ports an immediate response to pathogens under inﬂammatory
conditions.
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
The following reagents and chemicals were purchased or obtained
from the sources indicated: Lymphoprep (Axis-Shield, Oslo, Nor-
way); cell lysis buffer (Cell Signaling Technology, Danvers, MA,
USA); C1q (Comptech, Tyler, TX, USA); heat inactivated fetal
bovine serum (FBS; Hyclone, Logan, UT, USA); 100x Peni-
cillin/Streptomycin, RPMI 1640 (Gibco-Invitrogen, Grand Island,
NY, USA); Detoxi-Gel Endotoxin Removing Gel, p-nitrophenyl
phosphate (pNPP), EZ-Link Sulfo-NHS-LC-Biotin, Protein A
agarose, F(ab′)2 Micro Preparation Kit (Pierce, Rockford, IL,
USA); Complete protease inhibitor tablets (Roche Applied Sci-
ence, Indianapolis, IN, USA); human IgG, formalin (Sigma-
Aldrich, St. Louis, MO, USA). Antibodies used were against:
CD14 (BioLegend, San Diego, CA, USA); CD16, CD11c (Becton–
Dickinson, Mountain View, CA, USA); cC1qR (Serotec, Raleigh,
NC, USA); monoclonal (mAb) anti-globular and polyclonal anti-
body (pAb) against C1q, C4d (Quidel, Santa Clara, CA, USA);
ﬂuorescein isothiocyanate (FITC) conjugated goat anti-mouse IgG
F(ab′)2 or sheep anti-rabbit IgG F(ab′)2 (Invitrogen); and alkaline
phosphatase (AP)–conjugated rabbit anti-goat IgG (Pierce).
Because of the sensitivity of monocytes to endotoxin and
contaminating pathogen-associated molecular patterns (PAMPs),
highly puriﬁed and endotoxin-poor reagents and proteins were
purchased when possible. In addition, special efforts were made to
ensure that proteins used in the cell culture were low in endotoxin
by passage over Detoxi-Gel columns using pyrogen-free buffers.
The endotoxin removal efﬁciency in one passage is≥99% (Pierce).
MONOCLONAL AND POLYCLONAL ANTIBODIES TO C1s, C1r, C1
INHIBITOR, C4, AND FACTOR B
The production, characterization, and puriﬁcation of various
monoclonal and polyclonal antibodies to the gC1qR protein, as
well as to various peptides derived from the molecule have been
previously described (Ghebrehiwet et al., 1996; Hosszu et al.,
2010). Similarly, rabbit or goat pAbs to C1s, C1r, C1 inhibitor,
C4, and factor B were generated in our laboratory and constitute
part of our complement antibody bank. None of the antibod-
ies cross-reacted with bovine orthologs, as veriﬁed by enzyme-
linked immunosorbent assay (ELISA; data not shown). F(ab′)2
IgG fragments were prepared using a Pierce kit according to the
manufacturer’s instructions.
ISOLATION OF PERIPHERAL BLOOD MONOCYTES
Peripheral blood monocytes were isolated according to previously
published methods (Hosszu et al., 2010). Brieﬂy, PB mononuclear
cells were puriﬁed from whole blood using Lymphoprep density
gradient centrifugation according to the manufacturer’s instruc-
tions. Monocytes were further puriﬁed by adhesion selection on
polystyrene plates (1 h, 37˚C). Apart from monocyte/DCs, all
other contaminating cell constituents (lymphocytes, platelets, red
blood cells, polymorphonuclear cells) were absent from the cul-
ture, as assessed by scatter proﬁles and microscopic observations.
Monocyte subset gates were calculated on the basis of forward
and side light scatter proﬁles and cell surface display patterns of
myeloid cell/DC associated markers (CD14, CD16, and CD11c).
The research was done in accordance with the NIH guidelines for
human subjects and approved by the Stony Brook institutional
review board (#02626-5), and all human participants donating
blood gave written informed consent.
IMMUNOFLUORESCENCE MICROSCOPY
Cell surface staining of freshly obtainedmonocytes was performed
as follows. The cells were isolated as described above, then washed
twice in PBA staining buffer (PBS containing 1% BSA and 0.01%
NaN3). Non-speciﬁc binding was blocked by incubating the cells
with 1mg/ml human IgG in 100μl PBA/1× 106 cells (30min,
4˚C) and primary Abs or the appropriate isotype-matched con-
trols were then added to the cells (30min, 4˚C). The cells were
washed in PBA buffer and further incubated with FITC conju-
gated goat anti-mouse IgG F(ab′)2 (30min, 4˚C). The cells were
washed in cold PBA, ﬁxed for 5min in 1% PBS buffered formalin,
and washed with cold PBA. The cells were ﬁnally concentrated
by centrifugation, and applied to microscope slides, and allowed
to air dry. Subsequently cover slips were mounted onto the slides
using Immuno-mountmounting solution. The slides were viewed
on a Zeiss Axiovert 200 M digital deconvolution microscope, fol-
lowed by image capture at 63× (oil) magniﬁcation and analysis
with AxioVision 4.5 software. The results represent the analysis of
100 cells in three independent experiments.
FLOW CYTOMETRY ASSISTED ANALYSIS OF CELL SURFACE MARKERS
Cells were removed from the culture daily and washed twice in
PBA staining buffer. Non-speciﬁc binding was blocked by incu-
bating the cells with 1mg/ml human IgG in 100μl PBA/1× 106
cells (30min, 4˚C) and primary Abs or the appropriate isotype-
matched controls were then added to the cells (30min, 4˚C). The
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cells were then washed in PBA buffer and further incubated with
FITC conjugated goat anti-mouse IgG F(ab′)2 or sheep anti-rabbit
IgGF(ab′)2 (30min,4˚C). The cells werewashed in cold PBA,ﬁxed
in 1% formalin, and assessed by ﬂow cytometric analysis using
FACSCalibur (Becton–Dickinson,Mountain View, CA, USA). For
each analysis, 10,000 events were collected and the data obtained
was analyzed using CellQuest Pro software (BD).
DETECTION OF CELL SURFACE C1q BY ELISA
For detection of surface-speciﬁc C1q, U937 cells were ﬁrst sur-
face biotinylated using sulfo-NHS-LC-biotin according to the
manufacturer’s instructions, followed by cell lysis in a commer-
cially available cell lysis buffer according to the manufacturer’s
instructions. The presence of C1q was tested in each sample by
ELISA. To detect surface C1q, surface biotinylated cell lysates were
captured on microtiter plates coated with streptavidin or BSA
(negative control) at a concentration of 5μg/ml in coating buffer
(100mM Na2CO3/NaHCO3, pH 9.6). Non-speciﬁc binding sites
were blocked using 3%heat inactivated (56˚C, 90min) BSA in PBS
(1 h, 37˚C). In our experience, we have found that even the highest
grade BSA can contain trace amounts of C1q, therefore we rou-
tinely use heat inactivated and microﬁltered BSA. Because bovine
complement is unusually resistant to heat inactivation, a 90-min
incubation at 56˚C is necessary to ensure destruction of C1q activ-
ity. Highly puriﬁed serum C1q was used as positive control. BSA
was used as a negative control. Next, a C1q-speciﬁc polyclonal Ab
was added (1 h, 37˚C), followed by detection of the reaction with
AP–conjugated rabbit anti-goat IgG (1 h, 37˚C). All these steps
were performed in ELISA buffer (PBS, 0.1% BSA, 0.05% Tween
20) and each step was followed by three washes with PBS/0.05%
Tween 20. Enzyme activity was assessed by the addition of the sub-
strate pNPP. The optical density (OD) at 405 nm was measured
using a microplate reader at various time points.
WESTERN BLOTTING
U937 cell lysates were prepared using a non-ionic cell lysis buffer
(20mM Tris–HCL (pH 7.5), 150mM NaCl, 1mM EDTA, 1% Tri-
ton) supplemented with a protease inhibitor cocktail, according
to the manufacturer’s speciﬁcations. Proteins in the U937 whole
cell lysates were separated by SDS-PAGE using a 12% gel, trans-
ferred to a nitrocellulosemembrane, blocked in 5%milk (1 h, RT),
and incubated with primary antibodies (O/N, 4˚C). The mem-
brane was washed three times in TBS containing 0.05% Tween,
and incubated with secondary Abs conjugated to HRP (1 h, RT).
The blot was developed using SuperSignal West Pico-ECL detec-
tion reagent according to the manufacturer’s speciﬁcations and
visualized by exposing to Kodak Scientiﬁc Imaging X-OMAT ﬁlm.
DETECTION OF COMPLEMENT ACTIVATION BY C4 DEPOSITION
Poly-l-Lysine-coated microtiter plate wells (50μl/well, 10μg/ml
in PBS) were incubated with 50μl of U937 cells (2× 106 cells/ml
in PBS; 30min, RT). The plates were spun (5min, 400× g ), and
the cells ﬁxed using 50μl of 0.5% glutaraldehyde in PBS (30min,
RT). Next, the cells were washed twice in PBS and non-speciﬁc
binding was blocked using 0.1% BSA+ 100mM glycine (30min,
RT). The BSA for coating was always heat inactivated (90min,
56˚C) to inactivate trace amounts of bovine C1q and microﬁl-
tered to remove large aggregates. At this point the cells can be
used immediately or stored in blocking solution at −20˚C until
needed. On the day of the experiment the cells were thawed and
the blocking solution aspirated. Then 100μl Clq depleted serum
was added (1:10 dilution in 0.1% gelatin containing veronal buffer,
GVB) ±1mg/ml aggregated IgG ±200 ng/ml C4 (1 h, 37˚C). After
washing the cells with GVB, complement activation was assessed
by incubation with biotinylated anti-C4d tomeasure the C4d gen-
erated (1 h, 37˚C). After incubation the cells were again washed in
GVB, and incubated with AP-conjugated neutrAvidin (1 h, RT),
followed by the addition of the substrate pNPP. The OD at 405 nm
was measured using a microplate reader at various time points.
C1q-depleted serum alone was used as the negative control.
DETECTION OF U937 CELL SURFACE-ASSOCIATED C1 COMPLEX
ACTIVITY
U937 cells (2× 106 cells/sample) were washed twice in PBS. To the
cells we added 1μg puriﬁed C2+ 1μg puriﬁed C4+ 5μg aggre-
gated IgG± 1μg C1 in 0.1% GVB (2 h, 37˚C). After incubation
the supernatant was collected and C4 cleavage was assessed by
SDS-PAGE and Western blotting.
DETECTION OF COMPLEMENT ACTIVATION BY HEMOLYTIC ASSAY
The activity of U937-expressed C1q was assessed in the following
manner. First U937 cells (2× 106/sample) were washed in PBS,
mixed, and incubatedwith human sera diluted 1:10 inGVB± 5μg
aggregated IgG (1 h, 37˚C, in a shaking water bath). After incu-
bation, antibody-sensitized sheep erythrocytes (EAs) were added
to each sample and further incubated (1 h, 37˚C). The cells were
then centrifuged (5min, 800 rpm) and the released hemoglobin
measured in the supernatants spectrophotometrically at 415 nm
in order to assess the residual classical pathway activity. The total
hemolysis was obtained using sheep erythrocytes lysed in water.
C1q-depleted human sera reconstituted with increasing concen-
trations of C1q (0–100 ng) were used to develop a standard curve.
All hemolysis data points were presented as the percentage of
the complete hemolysis, calculated with the ratio between the
value measured for each sample and that registered for the total
hemolysis.
STATISTICAL ANALYSIS
Student t -tests were performed using statistical software (Excel;
Microsoft, Redmond, WA, USA). A value of p ≤ 0.05 was consid-
ered to be a signiﬁcant difference. (n values represent separate
experiments performed using different donors.)
RESULTS
C1q IS PRESENT ON THE SURFACE OF HUMAN MONOCYTES AND U937
CELLS
To investigate the role of C1q on monocytes, we ﬁrst analyzed
its surface expression on PB monocytes and on the monocyte-
derived U937 cell line. PB monocytes from healthy individuals
were isolated and subjected to indirect cell surface staining and
microscopic analyses. Our results conﬁrmed the presence of C1q
on monocytes, and revealed a punctate pattern of C1q evenly dis-
tributed over the cellular membrane (Figure 1A; right panel),
while isotype-matched non-immune Ab gave little or no signal
(Figure 1A; left panel). In order to gain insight into the role of
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FIGURE 1 | Monocytes display C1q on their surface. (A) C1q is present
on the surface of mononuclear cells. Fresh mononuclear cells were
stained with anti-C1q or an isotype control and detected using
PE-conjugated secondary Ab. Cells were applied to microscope slides and
viewed on a Zeiss Axiovert 200 M digital deconvolution microscope at 63×
(oil). Monocytes were identiﬁed by co-staining for monocyte speciﬁc
markers (not shown) in addition to anti-C1q. (B) C1q is expressed on the
surface of U937 cells. Biotinylated U937 cell membrane proteins were
captured on a streptavidin-coated ELISA plate and the binding of C1q was
detected using pAb RaH C1q. Rabbit IgG was used as an isotype control
(n=2). (C+D) C1q is present on the surface of U937 cells as assessed by
ﬂow cytometry. U937 cells were stained with GaH C1q followed by
secondary Ab conjugated to Alexa 488. One experiment is shown (C),
representative of six experiments (D).
surface C1q on monocytes, we employed the commercially avail-
able monocyte-derived U937 cell line as a surrogate. As expected,
the presence of C1q on the surface of these cells was veriﬁed by
antigen-capture ELISA experiments. Using cell membranes iso-
lated fromU937 cells, we showed the presence of C1q (Figure 1B),
while an isotype-matched non-immune rabbit Ab showed neg-
ligible staining. We further conﬁrmed these results using ﬂow
cytometric analysis, ﬁrmly establishing the presence of surfaceC1q
onU937 cells (Figures 1C,D). These data are consistentwithprevi-
ously published results showing that C1q is present on the surface
of monocytes (Hosszu et al., 2010) and U937 cells (Arvieux et al.,
1984).
MACROMOLECULAR C1 COMPLEX IS PRESENT ON THE SURFACE OF
HUMAN MONOCYTES
Since most of the C1q – save approximately 20% – circulates in
plasma as part of the multimeric C1 complex (C1q1C1r2–C1s2),
we hypothesized that the C1q detected on the monocyte surface
may be part of the C1 complex. To test this premise, monocytes
were analyzed for surface expression of C1s and C1r, using ﬂow
cytometry. In addition, two other complement proteins, Factor B
and C1 inhibitor, were assessed as well. Using cell surface stain-
ing and ﬂow cytometric analysis, we found that in addition to
C1q, nearly all monocytes were positive for the presence of both
C1r and C1s (Figures 2A,B). Furthermore, C1-Inh was also on
the cells, possibly ensuring that unwarranted classical comple-
ment activation does not take place through the surface bound
C1 complex.We were also able to detect the components of the C1
complex onU937 cells by ﬂow cytometric analysis (Figures 2C,D).
Additionally,Western blotting conﬁrmed the presence of C1s and
C1r in U937 cell lysates (Figure 2E). Not surprisingly, Factor B,
a complement protein synthesized by monocytes (Hogasen et al.,
1995), was also found on the cells. Next we investigated whether
C1s, C1r, and C1q assemble into the C1 complex on U937 cells. As
Figure 2F shows anti-C1q conjugated agarose beads were able to
pull down C1s and C1r from U937 whole cell lysates, conﬁrming
that the entire C1 complex is present on the cell surface.
To examine whether the level of these surface molecules
decreases over time, we cultured U937 cells in serum-free (SF)
media for 48 h, ensuring that the surface molecules could not be
replenished from the media over time. Interestingly, we detected
no signiﬁcant change in the cell surface levels of C1q or C1r
after 48 h, while C1s, Factor B, and C1 inhibitor all signiﬁcantly
decreased on the surface of U937 cells (Figures 3A,B). To inves-
tigate whether the surface molecule loss of C1s, Factor B, and C1
inhibitorwas due to endocytosis or external release,we determined
the levels of all ﬁve molecules in the SF supernatant of U937 cell
cultures by Western blotting. Figure 3C shows that C1s, Factor
B, and C1 inhibitor were all readily detected in the supernatants,
while no detectable quantities of C1q or C1r were released over
the 48-h culture period.
C1 COMPLEX ON U937 CELLS TRIGGERS COMPLEMENT ACTIVATION
Next we sought to determine the functional signiﬁcance of the
C1q on U937 cells by assessing the ability of the surface C1q to
activate the classical complement pathway. U937 cells attached to
microplate wells were incubated with C1q-depleted human sera,
andmixedwith aggregated IgG andC4, followed by detectionwith
an anti-C4d mAb. As expected, the C1q on the surface of U937
cells was able to initiate complement (Figure 4A) as evidenced by
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FIGURE 2 | C1 complex is located on the surface of monocytes. (A+B) C1
complex is present on the surface of human monocytes as assessed by ﬂow
cytometry. Human monocytes were isolated from whole blood and stained
with GaH C1s, C1r, C1q, or RaH C1-Inh, Factor B Ab followed by secondary
Ab conjugated to Alexa 488. One experiment is shown (A), representative of
three experiments (B). (C+D) C1 complex is present on the surface of U937
cells as assessed by ﬂow cytometry. U937 cells were stained with GaH C1s,
C1r, C1q, or RaH C1-Inh, Factor B Ab followed by secondary Ab conjugated to
Alexa 488. One experiment is shown (C), representative of six experiments
(D). (E) C1s and C1r are produced by U937 cells. U937 whole cell lysates
were subjected to SDS-PAGE and subsequently visualized byWestern blotting
using GaH C1s and RaH C1r, followed by HRP-conjugated secondary Abs.
Puriﬁed C1s and C1r were run as positive controls (n=3). (F) C1 complex is
formed on U937 cells. Anti-C1q conjugated agarose beads were incubated
with U937 whole cell lysates. The bound proteins were subjected to
SDS-PAGE followed byWestern blotting using anti-C1s and anti-C1r and
HRP-conjugated secondary Abs. Puriﬁed C1s and C1r were run as positive
controls (n=2).
the formation of C4d. Aggregated IgG alone was able to produce
C4d, but to a lesser degree than when additional C4 was supple-
mented to the reaction, indicating the rapid consumption of the
C4 available in the system (Figure 4A).
Assessment of in vitro hemolytic activity of the C1q on U937
cells using sheep erythrocytes was also performed (Figure 4B).
Cells pre-incubated with C1q-depleted human serum induced
depletion of total complement hemolytic activities (Figure 4B).
The amount of hemolytically active surface C1q was quantiﬁed
using the dose-dependent curve, whereby increasing concentra-
tions of C1qwere added to C1q-depleted human sera and comple-
ment pathway activity was measured. Calculated from the linear
progression curve, the hemolytic activity of 2× 106 U937 cells
was equivalent to 20 ng C1q (Figure 4B). Based on this num-
ber, each U937 cell has 10 fg C1q on its surface, which represents
approximately 10,000C1qmolecules/cell. These experiments indi-
cate that U937 cell surface-associated C1q is able to contribute to
the activation of the classical pathway.
Next we sought to determine whether the entire C1 complex
was functional on the surface of these cells. When U937 cells were
mixed with puriﬁed C2, C4, and aggregated IgG, the C1 complex
on U937 cells was able to cleave C4, as evidenced by the inac-
tivated C4b cleavage product, iC4b (Figure 4C). Taken together
these experiments suggest that the C1 complex is fully assembled
on the surface of U937 cells and it is able to initiate the classical
complement cascade.
DISCUSSION
The consensus that almost all of the complement proteins are
synthesized in the liver has been gradually challenged over the
years by ﬁndings that demonstrate extrahepatic synthesis of a wide
array of complement proteins and their regulators (Laufer et al.,
2001). In particular, the multimolecular C1 complex and its regu-
lator, C1 inhibitor, have been shown to be synthesized by human
monocytes and the monocyte-derived U937 cell line (Bensa et al.,
1983; Randazzo et al., 1985; Tenner and Volkin, 1986; Drouet and
Reboul,1989;Gulati et al., 1993; Lu et al., 1996;Moosig et al., 2006).
Our previously published data have shown that C1q is present on
the surface of circulating monocytes (Hosszu et al., 2010). Since
monocytes produce all components of the C1 complex, here we
sought to investigate whether the cell surface C1q is part of the
C1 macromolecular complex. Our data show, that contrary to the
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FIGURE 3 | Surface levels of C1 complex components decrease over time
on U937 cells. (A+B) C1s, Factor B, and C1 inhibitor are lost from the
surface of U937 cells after 48 h. U937 cells were grown in RPMI+10% FBS
(+ serum) or in Macrophage Serum-Free Media (-serum) for 48 h and stained
with GaH C1q, C1s, C1r, or RaH C1-Inh, Factor B and isotype-matched
controls followed by secondary Ab conjugated to Alexa 488. The cells were
analyzed by ﬂow cytometry. One experiment is shown (A), representative of
three experiments. (B) *p ≤0.05; **p ≤0.01 (C) C1 complex components are
released into the supernatant of U937 cells. Supernatants of U937 cell
cultures were subjected to SDS-PAGE and subsequently visualized by
Western blotting using the same primary Abs as above, followed by
HRP-conjugated secondary Abs (n=3).
previously held postulate that macrophages and maturing DCs,
but not monocytes express C1q (Kaul and Loos, 2001; Vegh et al.,
2003), freshly isolated PB monocytes and U937 cells also express
not only C1q, but also the other subcomponents of C1, namely
C1r and C1s, as well as the regulator, C1-Inh.
The presence of C1-Inh on the surface is signiﬁcant, as it inti-
mates that C1-Inh closely monitors the role of the C1 complex
in a sterile or infectious microenvironment and inﬂammation.
Monocyte-associated C1-Inh may regulate how C1q, which binds
to a plethora of microbial or non-microbial activators at inﬂam-
matory sites, can communicate with DCs or T cells to enhance
or abort immune responses. Under physiological conditions com-
plement activation is tightly regulated to prevent complement-
mediated tissue damage. The presence of C1-Inh with the C1
complex probably represents a primary level of protection against
autoimmunity.
Our data indicate that the C1 complex on the surface of U937
cells is able to initiate the classical complement cascade. When
U937 cells – as a source of C1 complex – were incubated with
puriﬁed C2 and C4, we were able to detect iC4b, an inactive cleav-
age product of C4b in the cell supernatants. The amount of activity
initiated by 2× 106 U937 cells was equivalent to that of approx-
imately 20 ng of puriﬁed C1q, as measured by in vitro hemolytic
activity using sheep erythrocytes. These data suggest that under
pathogenic conditions, pathogen associated, or self-derived mol-
ecules can trigger complement activation in close proximity to
the monocyte surface. Self-damage is controlled by the presence
and quick removal of C1r2–C1s2 by C1-Inh, and in turn by the
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FIGURE 4 | Surface-associated C1 complex of U937 cells can initiate
complement activation. (A) C1q on the surface of U937 cells triggers
the complement cascade of the classical pathway. U937 cells were
attached to a microtiter plate and incubated with a 1:10 dilution of Clq
depleted serum (C1qDpl)± aggregated IgG (Agg IgG)±C4. Activation of
complement was detected by sequential addition and incubation of
biotinylated anti-C4d Ab, alkaline phophatase conjugated neutrAvidin,
followed by pNPP. C1q-depleted serum was used as a negative control
(n=3) *p<0.05. (B) Surface C1q on U937 cells activates complement in
a hemolytic assay. 2×106 U937 cells were incubated with C1q-depleted
serum± aggregated IgG (Agg IgG)+Ab-sensitized sheep erythrocytes
(EAs). The residual complement activity was assessed by addition of EAs.
C1q-depleted human serum reconstituted with increasing concentrations
of C1q (0–100 ng) was used for the standard curve and as a positive
control (n=2). (C) C1 complex on U937 cells is able to cleave C4. U937
cells were incubated with puriﬁed C2 and C4+Agg IgG for 2 h at 37˚C.
The supernatants were collected, the proteins were separated on
SDS-PAGE, followed byWestern blotting with anti-C4 and
HRP-conjugated secondary Ab. C1 complex was added to the cell mixture
as positive control (n=2).
rapid capture and proteolysis of C2 and C4. Thus, C1 complex
on monocytes may have implications for immediate response to
pathogens under inﬂammatory conditions, and C1q and the C1
complex may act as an “early warning” autocrine sensor of dan-
ger and assist to instantaneously “chaperone” extracellular Ag for
uptake into monocytes.
Under physiological conditions, surface-associated C1 com-
plex – similar to surface-associatedC1q (Hosszu et al., 2010) –may
also function as an early signalingmolecule onmonocytes andmay
reﬂect an as yet unidentiﬁed regulatory mechanism that sustains
innate immune functions.
Although previous reports have documented that PB mono-
cytes, including those obtained from C1-Inh deﬁcient patients are
capable of producing C1-Inh (40%of normal; Lappin et al., 1989),
and our own work has demonstrated the synthesis of this protein
by the monocyte-like cell line U937 (Randazzo et al., 1985), what
remains to be determined is how the C1 complex and C1-Inh are
anchored on the surface. Indeed, real-time antigen-capture assay
(not shown) has shown that U937 cells, grown in serum-free cul-
ture medium can produce measurable amounts of C1q, C1r, and
C1s, indicating that these cells actively synthesize and secrete these
proteins. Although experiments are undergoing to conﬁrm such a
scenario,we speculate that themost likely anchoring protein in this
complex would be C1q, which could be anchored by a short trans-
membrane collagen piece similar to that described earlier (Kaul
and Loos, 1995) on the surface of monocyte-derivedmacrophages.
This transiently expressed C1 complex on the monocyte sur-
face may be later cleaved off and released into the pericellular
milieu.
Alternatively, circulating C1 complex may be captured from
blood by monocytes via cell surface receptors. Two C1q recep-
tors, gC1qR and cC1qR (calreticulin) have been well described on
the monocyte surface (Malhotra, 1993; Ghebrehiwet et al., 1994).
Additionally, the presence of otherC1q-binding surfacemolecules,
such as SIGN-like C-type lectins and beta-1 integrins have been
shown (Tuckwell et al., 1996; Kang et al., 2006). Circulating C1
complex may be captured from blood and retained on the cell
surface through these receptors.
In summary, our results show that the entire multimolecular
C1 complex is present on the surface of monocytes and U937
cells, and suggests that surface-associated C1 complex is actively
able to ﬁx complement in the presence of an extracellular antigen,
thus providing antigenic material for cellular uptake in the vicin-
ity of the cell. This suggests a novel role for locally synthesized
C1q, and since monocytes are critical in the adaptive and innate
arms of immunity, the presence and functional activity of the C1
complex on their surface may indicate a new form of a molec-
ular sensor of “danger” signals that could provide an immediate
local response to either pathogen- or damage-associatedmolecular
ligands.
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